Skip to main content
Choose your location
Select the location and the language that you prefer

main content, press tab to continue

Through a new lens: Managing the risks of AI wearables in healthcare

Author

Joan M. Porcaro and
Dr. Harriet Lewis
July 14, 2026

This is a timely issue for healthcare organizations. Smart glasses introduce a new category of privacy, security, and professional practice risk because they combine a wearable camera, microphone, AI assistant, wireless connectivity, and cloud-based processing into a device that is difficult for others to recognize as actively recording.

From a healthcare risk management perspective, treating Smart glasses the same or even more conservative than smartphones because of their discreet nature seems prudent.

From a regulatory standpoint, the primary risk is not that smart glasses are inherently noncompliant, but that they lack the administrative, technical, and contractual safeguards required for handling protected health information (PHI). HIPAA applicability depends on how data are used; depending on how wearable-generated information is collected, maintained, used, or disclosed by a covered entity or business associate, it may constitute PHI and become subject to HIPAA protections. At the same time, smart glasses fall within a broader patchwork of legal frameworks, including HIPAA, wiretap laws, and biometric privacy statutes rather than a device-specific regulatory scheme.

Overall current literature supports a cautious approach.

Primary HIPAA concerns

The biggest concern is not necessarily that smart glasses are inherently "non-HIPAA compliant." Rather, the concern is that they were not designed as enterprise healthcare devices and currently may not provide all of the administrative, technical, and contractual safeguards typically required for handling protected health information (PHI). However, HIPAA does not universally apply to devices unless integrated into care workflows

Examples include:

  • Continuous microphones that may inadvertently capture patient conversations.
  • Camera recording without patients or staff recognizing recording is occurring.
  • AI processing that may send information to cloud services.
  • Storage of images and audio outside the healthcare organization's control.
  • Automatic synchronization with personal smartphones and cloud accounts.
  • Lack of Business Associate Agreements (BAAs) for consumer AI features.
  • Limited enterprise device management capabilities.

Risk assessment questions

Before permitting these devices, organizations should perform a formal risk assessment asking the following:

Clinical Use

  • Why are Smart glasses being used?
  • Is there a legitimate clinical purpose?
  • Does another approved technology already exist?

Privacy

  • Can PHI be recorded?
  • Can conversations be captured?
  • Can other patients be unintentionally recorded?

Security

  • Where is the data stored?
  • Is the data encrypted?
  • Who owns the account?
  • Can recordings be remotely deleted?

Regulatory

  • Does the vendor offer a BAA?
  • Does use comply with HIPAA?
  • Does use comply with applicable state privacy laws?

Governance recommendations

A multidisciplinary review committee should evaluate wearable AI technologies before deployment, including representatives from:

  • Risk Management
  • Privacy
  • Information Security
  • Compliance
  • Clinical Operations
  • Legal Counsel
  • Health Information Management
  • Biomedical Engineering/Clinical Engineering
  • Information Technology

The committee should conduct a formal technology assessment addressing privacy, security, patient safety, workflow, regulatory requirements, and organizational readiness before approving any clinical use. A sample health system policy found online is noted here.

Risk manager takeaway

Smart glasses should be viewed as an emerging AI-enabled clinical technology rather than simply another wearable device. Healthcare organizations should require formal risk assessment, vendor due diligence, enterprise governance approval, and clear policies before permitting their use in patient care areas. Until enterprise-grade controls including appropriate privacy safeguards, security management, and contractual protections are available and validated, a cautious approach is warranted, particularly in environments where PHI, patient trust, and clinical decision-making are central to care.

Overall, literature supports a cautious approach. Smart glasses are best understood as an emerging AI-enabled clinical technology that requires formal risk assessment, structured governance, and clearly defined use cases. Until enterprise-grade safeguards including robust privacy controls, security management, and contractual protections are consistently available, healthcare organizations should implement conservative policies and carefully limit use in patient care environments.

References

  1. Diaz N. Smart glasses spotlight privacy blind spots in healthcare. Becker’s Hospital Review. December 18, 2025. Accessed June 29, 2026. View article
  2. Lazzarotti JJ. The hidden legal minefield: compliance concerns with AI smart glasses—Part 4: data security, breach notification, and third-party AI processing risks. Workplace Privacy Report. January 16, 2026. Accessed June 29, 2026. View article
  3. Total Medical Compliance. Using AI in healthcare: key compliance considerations for tools and devices. Accessed June 29, 2026. View article
  4. HIPAA Partners. HIPAA wearable device compliance: complete integration guide. January 5, 2026. Accessed June 29, 2026. View guide
  5. Jodka S. When the microphone lives on your face: smart glasses in the workplace and the clinic. Health Law Blog. June 1, 2026. Accessed June 29, 2026. View article
  6. Simbo AI. Ensuring HIPAA compliance and data security in AI-driven wearable healthcare solutions. Accessed June 29, 2026. View article
  7. PYA. Smart glasses in healthcare: benefits, risks, and compliance considerations. February 6, 2026. Accessed June 29, 2026. View article
  8. UW Medicine. Wearable technology guidance. Accessed June 29, 2026. View guidance

Disclaimer

WTW hopes you found the general information provided here informative and helpful. The information contained herein is not intended to constitute legal or other professional advice and should not be relied upon in lieu of consultation with your own legal advisors. In the event you would like more information regarding your insurance coverage, please do not hesitate to reach out to us. In North America, WTW offers insurance products through licensed entities, including Willis Towers Watson Northeast, Inc. (in the United States) and Willis Canada Inc. (in Canada).

Authors

Joan M. Porcaro, Senior Vice President, Risk Services - Healthcare

Joan M. Porcaro

Senior Vice President, Risk Services - Healthcare

Dr. Harriet Lewis, Associate Director, Clinical Risk Consultant - Global FINEX Healthcare

Dr. Harriet Lewis

Associate Director, Clinical Risk Consultant - Global FINEX Healthcare